AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 171 min read$FOCL

LEVINE JOSHUA purchased $48K of FOCL

LEVINE JOSHUA purchased 10,000 shares of EDAP TMS SA (FOCL) at $4.75 on 2026-08-14.

Original reporting
SEC EDGAR · LEVINE JOSHUA
Published Aug 17, 2026, 10:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FOCL
Bullish
low confidence
Mentioned
$FOCL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FOCLBullishLow
01

Why it matters

A director open-market purchase is incremental information for sentiment, but it does not change the company’s financial outlook or introduce new operational/regulatory facts.

02

Market read

Traders may note the insider buying as a small positive signal, but the lack of company-specific news limits tradable impact.

03

What to watch

The article provides no context on motivation, whether the purchase was part of a broader pattern, or whether other insiders were buying or selling around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for EDAP TMS SA (FOCL).

Company-level read

Ticker impact

$FOCLBullishLow confidence
Context

EDGAR Form 4 shows director Joshua Levine bought 10,000 shares of FOCL at $4.75 on 2026-08-14, lifting holdings to 45,000.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company news, guidance, or operational change.

Market effects

Sector

No sector-wide signal; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be discretionary and may not reflect near-term fundamentals, especially without a broader company catalyst.

Key entities

  • issuer
    EDAP TMS SA

    Company subject of the Form 4 insider transaction disclosure (FOCL).

  • insider
    LEVINE JOSHUA

    Director who reported an open-market purchase of 10,000 shares at $4.75 on 2026-08-14.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FOCL insider trading history →

Related articles

AUG 18
$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

yahoo.com7 min
AUG 14
$FOCLMed

FocalTherics Q2 Earnings Call Highlights

FocalTherics (NASDAQ:FOCL) reported Q2 highlights from its earnings call. U.S. Focal One procedure volumes rose 47% YoY. HIFU gross margin increased to 55.6% from 51.1%. Cash was $21.5M and it drew about €14M under its EIB credit facility. The company plans a $40M Aug. 14 offering and reiterated 2026 HIFU revenue guidance of $50M to $54M.

finance.yahoo.com6 min
AUG 13
$FOCLMedAI 8/10

FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M

FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.

tradingview.com1 min
AUG 13
$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial resul

SEC EDGAR 8-K6 min
AUG 12
$FOCLMed

FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down

FocalTherics (FOCL) reported preliminary unaudited Q2 2026 results. Revenue is expected at $12.7 to $13.2 million, up 34% to 39% from $9.7 million in Q2 2025, with gross margin at 54% to 56% versus 42.5%. Cash and investments were $21.5 million as of June 30. The company priced a public offering of 8.425M ADS at $4.75 to raise about $40M gross, with an option for 1.26375M more ADS.

rttnews.com4 min
AUG 11
$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com

SEC EDGAR 8-K6 min